Therapeutic lag in reducing disability progression in relapsing-remitting multiple sclerosis: 8-year follow-up of two randomized add-on trials with atorvastatin
DiscussionThese data suggest that a delayed treatment effect maybe seen with atorvastatin added to interferon-beta, eight years after entering the clinical trials. Long-term follow-up of trial cohorts should be mandated.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
More News: Atorvastatin Calcium | Clinical Trials | Disability | Lipitor | Multiple Sclerosis | Statin Therapy | Zivast